Visualize Better Lead Compounds
Making smart decisions at the Lead Discovery stage is a key factor in implementing a successful Drug Discovery and Development program. Only one out of ten drugs succeeds in the clinic, meaning that 90% of all ongoing drug programs are essentially doomed. How can these failures be prevented, leading more programs to successful outcomes? Fragment-based Lead Discovery (FBLD) is a method whereby smaller compound libraries are screened using structural, biophysical and biochemical methods, resulting in information that is used to generate novel leads. The technology has been driven by faster access to structure-based drug design and screening, utilizing methods developed by companies such as ActiveSight. By leveraging ActiveSight's FBLD capabilities and expertise, you can take advantage of all of the benefits of FBLD without the capital expenditure normally required.

World-class Expertise
ActiveSight's Management has over 45 years of experience in X-ray crystallography and structure-based drug design, solving several hundreds of novel and co-crystal structures. ActiveSight's scientific team has cloned, expressed, crystallized, and solved the structures of over 100 human drug targets. As a result, ActiveSight has established itself as the premier structure-based drug design partner, working with over 35 pharmaceutical and biotechnology companies. We've expanded our capabilities with our integrated FBLD LENS™ Technology, adding several complementary lead discovery technologies and state-of-the-art chemistry, providing our partners with the ability to generate tightly-binding lead compounds efficiently and effectively.

Partner With Us
With broad-ranging expertise, experienced project management, and flexible intellectual property models, ActiveSight is the premier Lead Discovery partner. Contact us to schedule a visit or web-based presentation, so that you can learn how we can work with you to fill or boost your pipeline with high-quality lead compounds.